{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:21:01Z","timestamp":1789791661180,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06711"],"award-info":[{"award-number":["21K06711"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.dmpk.2023.100529","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:49:03Z","timestamp":1693568943000},"page":"100529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A model-based pharmacokinetic assessment of drug\u2013drug interaction between tacrolimus and nirmatrelvir\/ritonavir in a kidney transplant patient with COVID-19"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4223-9320","authenticated-orcid":false,"given":"Takeshi","family":"Tomida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-7881","authenticated-orcid":false,"given":"Kotaro","family":"Itohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7513-6725","authenticated-orcid":false,"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Uda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0263-5726","authenticated-orcid":false,"given":"Yumi","family":"Kitahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-0981","authenticated-orcid":false,"given":"Yoji","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-253X","authenticated-orcid":false,"given":"Tomohiro","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.dmpk.2023.100529_bib1","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/ndt\/gfab200","article-title":"COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study","volume":"36","author":"Goffin","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.dmpk.2023.100529_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.kint.2021.05.011","article-title":"French Society of Transplantation. Occurrence of severe COVID-19 in vaccinated transplant patients","volume":"100","author":"Caillard","year":"2021","journal-title":"Kidney Int"},{"issue":"15","key":"10.1016\/j.dmpk.2023.100529_bib3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.dmpk.2023.100529_bib4","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmpk.2023.100529_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1742-7843.2006.pto_249.x","article-title":"Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in\u00a0vitro","volume":"98","author":"Granfors","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"10","key":"10.1016\/j.dmpk.2023.100529_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0006-2952(99)00026-X","article-title":"HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833","volume":"57","author":"Drewe","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.dmpk.2023.100529_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100529_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2001.115142","article-title":"Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation","volume":"69","author":"Hashida","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2023.100529_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif Organs"},{"issue":"9","key":"10.1016\/j.dmpk.2023.100529_bib10","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1124\/dmd.111.039248","article-title":"Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction","volume":"39","author":"Gertz","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmpk.2023.100529_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/psp4.12420","article-title":"A\u00a0minimal physiologically-based pharmacokinetic model for tacrolimus in living-donor liver transplantation: perspectives related to liver regeneration and the cytochrome P450 3A5 (CYP3A5) genotype","volume":"8","author":"Itohara","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2023.100529_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.transproceed.2022.04.015","article-title":"Paxlovid (Nirmatelvir\/Ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report","volume":"54","author":"Prikis","year":"2022","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1016\/j.dmpk.2023.100529_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13181-022-00922-2","article-title":"Tacrolimus drug-drug interaction with nirmatrelvir\/ritonavir (Paxlovid\u2122) managed with phenytoin","volume":"19","author":"Sindelar","year":"2023","journal-title":"J\u00a0Med Toxicol"},{"issue":"1","key":"10.1016\/j.dmpk.2023.100529_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.healun.2022.08.029","article-title":"Risks of paxlovid in a heart transplant recipient","volume":"42","author":"Stawiarski","year":"2023","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.dmpk.2023.100529_bib15","article-title":"Management of nirmatrelvir\/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series","author":"Guzm\u00e1n Cordero","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100529_bib16","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/TP.0000000000004394","article-title":"Nirmatrelvir\/ritonavir use with tacrolimus in lung transplant recipients: a single-center case series","volume":"107","author":"Dewey","year":"2023","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.dmpk.2023.100529_bib17","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ajt.17027","article-title":"Early clinical experience with nirmatrelvir\/ritonavir for the treatment of COVID-19 in solid organ transplant recipients","volume":"22","author":"Salerno","year":"2022","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.dmpk.2023.100529_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2010.03837.x","article-title":"Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf","volume":"71","author":"Woillard","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2023.100529_bib19","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1016\/S0041-1345(98)01243-3","article-title":"FK 506 in cadaveric kidney transplantation from non-heart-beating donors","volume":"30","author":"Hattori","year":"1998","journal-title":"Transplant Proc"},{"issue":"10","key":"10.1016\/j.dmpk.2023.100529_bib20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/apc.2012.0169","article-title":"Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review","volume":"26","author":"van Maarseveen","year":"2012","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"10.1016\/j.dmpk.2023.100529_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/TP.0b013e3182734651","article-title":"Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study","volume":"95","author":"van Maarseveen","year":"2013","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100529_bib22","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/FTD.0000000000000315","article-title":"Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection","volume":"38","author":"Badri","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.dmpk.2023.100529_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","article-title":"Tacrolimus oral bioavailability doubles with coadministration of ketoconazole","volume":"62","author":"Floren","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmpk.2023.100529_bib24","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1097\/QAD.0b013e3280da8ba8","article-title":"Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients","volume":"21","author":"Autar","year":"2007","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.dmpk.2023.100529_bib25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/0091270006288733","article-title":"Time-dependent interaction between lopinavir\/ritonavir and fexofenadine","volume":"46","author":"van Heeswijk","year":"2006","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2023.100529_bib26","first-page":"404","article-title":"Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam","volume":"39","author":"Zhou","year":"2014","journal-title":"J\u00a0Clin Pharm Therapeut"},{"key":"10.1016\/j.dmpk.2023.100529_bib27","article-title":"Population pharmacokinetic analysis of drug-drug interactions between perampanel and carbamazepine using enzyme induction model in epileptic patients","author":"Fujita","year":"2022","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.dmpk.2023.100529_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","article-title":"CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients","volume":"82","author":"Kuypers","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100529_bib29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00228-008-0606-3","article-title":"CYP3A5 \u22171 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients","volume":"65","author":"Satoh","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2023.100529_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00008571-200206000-00009","article-title":"Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5\u22173 and \u22176, in a Japanese population","volume":"12","author":"Fukuen","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.dmpk.2023.100529_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clpt.2005.11.009","article-title":"Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir","volume":"79","author":"Culm-Merdek","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100529_bib32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.dmpk.2023.100529_bib33","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","article-title":"Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect","volume":"75","author":"Stader","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.dmpk.2023.100529_bib34","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ajt.17027","article-title":"Early clinical experience with nirmatrelvir\/ritonavir for the treatment of COVID-19 in solid organ transplant recipients","volume":"22","author":"Salerno","year":"2022","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.dmpk.2023.100529_bib35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.ajkd.2022.01.001","article-title":"Special considerations for Paxlovid treatment among transplant recipients with SARS-CoV-2 infection","volume":"79","author":"Fishbane","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.dmpk.2023.100529_bib36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/FTD.0000000000000761","article-title":"Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions","volume":"42","author":"Elens","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.dmpk.2023.100529_bib37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40780-023-00280-3","article-title":"A\u00a0case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir\/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis","volume":"9","author":"Tsuzawa","year":"2023","journal-title":"J\u00a0Pharm Health Care Sci"},{"issue":"2","key":"10.1016\/j.dmpk.2023.100529_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19","volume":"45","author":"Lemaitre","year":"2023","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2023.100529_bib39","author":"Japanese Society of Pharmaceutical Health Care and Sciences"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:57:26Z","timestamp":1761163046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436723000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":39,"alternative-id":["S1347436723000411"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100529","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A model-based pharmacokinetic assessment of drug\u2013drug interaction between tacrolimus and nirmatrelvir\/ritonavir in a kidney transplant patient with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100529"}}